Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) is a clinical-stage biopharmaceutical company focused on therapies built on its lipid nanocrystal (LNC) platform delivery technology. The Matinas news feed highlights developments around its lead antifungal candidate MAT2203, corporate strategy, and platform research, providing context for investors and observers tracking MTNB stock news.
Company news frequently covers clinical and medical updates for MAT2203, an oral formulation of amphotericin B being developed as a potential broad-spectrum treatment for invasive deadly fungal infections. Releases have described results from the Phase 2 EnACT study in HIV patients with cryptococcal meningitis, outcomes from the Compassionate/Expanded Use Access Program in patients with severe invasive fungal infections, and plans for the ORALTO Phase 3 registration trial in invasive aspergillosis. These items help readers understand how MAT2203 is performing in both controlled trials and real-world settings.
Matinas also issues corporate and strategic announcements, including updates on its strategic review, financing transactions such as preferred stock and warrant offerings, and responses to NYSE American listing notices. Board and governance news—such as the appointment of independent directors with expertise in biotechnology, healthcare, finance, and audit oversight, as well as director retirements and committee leadership changes—features prominently in the company’s communications.
In addition, the news stream includes scientific and platform data related to the LNC technology, such as in vitro and in vivo findings on LNC delivery of small oligonucleotides and chemotherapeutic agents, and conference presentations on intracellular delivery. Readers can use this page to follow how Matinas’ clinical programs, LNC platform research, and corporate actions evolve over time. For those monitoring MTNB, returning to this news page offers a centralized view of key press releases and event announcements.
Matinas BioPharma Holdings (NYSE: MTNB) announced that CEO Jerome D. Jabbour will participate in a fireside chat at the BTIG Virtual Biotech Conference on August 11, 2020, at 9:00 a.m. ET. He will also host investor meetings during the event. Interested investors can contact the conference coordinator for arrangements. A live webcast of the discussion will be available on the Company's website, with a replay accessible for 90 days. Matinas BioPharma focuses on developing MAT9001 for cardiovascular conditions and MAT2203 for serious fungal infections.
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) will host a conference call on August 10, 2020, at 4:30 p.m. ET to discuss its second-quarter operational and financial results for the period ending June 30, 2020. To participate, dial (877) 407-5976 for domestic or (412) 902-0031 for international calls. The call will also be accessible via a live audio webcast on the company's website. Matinas focuses on developing MAT9001 for hypertriglyceridemia and MAT2203 for serious fungal infections using its proprietary delivery technology.
Matinas BioPharma (MTNB) has resumed enrollment in its ENHANCE-IT study, comparing MAT9001 to Vascepa, with topline data expected in Q1 2021. Additionally, the company received regulatory approval to restart its EnACT study in Uganda. Expectations are set for rapid patient dosing and progression through clinical stages, indicating potential value creation for shareholders. The ENHANCE-IT study aims to generate clinically meaningful data to support MAT9001's efficacy in treating hypertriglyceridemia while the EnACT study focuses on treating cryptococcal meningitis.
Matinas BioPharma Holdings (MTNB) announced that CEO Jerome D. Jabbour will present a company overview at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 8:00 a.m. ET. He will also host investor meetings during this event. Interested investors can arrange meetings through the conference coordinator. A live webcast will be available on the company's IR calendar page, with a replay accessible for 90 days post-event. Matinas focuses on developing MAT9001 for cardiovascular and metabolic conditions and MAT2203 for serious fungal infections.
Summary not available.